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Both oxygen therapy and bronchodilators reduce exertional breathlessness and improve
exercise tolerance in patients with stable chronic obstructive pulmonary disease (COPD).
However their relative effectiveness and the value of their combined use on exercise
performance has not been assessed.
The effects of 5mg of salbutamol plus 500mg ipratropium bromide nebulisation followed by a
6-min walking test while breathing O2 were studied in a randomised, single-blind, placebo
controlled, crossover trial in 28 patients with severe or very severe COPD, breathless on
exertion and with oxygen saturationp89% at rest or on exercise. Bronchodilator reversibility
was minimal. The 6-min walking distance increased from 356 (128)m to 377 (117)m after the
bronchodilator (Po0.05), to 406 (109)m after supplementary oxygen but without
bronchodilators (P 0.011 versus bronchodilators/air and 0.001 versus placebo/air), and to
430 (109)m after the combination of oxygen and the bronchodilators (Po0.0001 versus
placebo/air and bronchodilators/air; P ¼ 0.014 versus placebo/oxygen). End-exercise
dyspnea only fell significantly when oxygen and bronchodilator were combined.
In severe or very severe COPD patients with relatively fixed airway obstruction
bronchodilators enhance exercise performance obtained with oxygen. Clinically relevant
improvement is possible when therapies with a different mechanism of action are combined.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Bronchodilators and oxygen in COPD 74725 years, a pre-bronchodilator forced expiratory volume inIntroduction
Breathlessness and reduced exercise capacity are the most
disabling symptoms in patients with chronic obstructive
pulmonary disease (COPD)1 and a major goal of treatment is
to reduce dyspnoea, improve exercise tolerance and
decrease handicap. Several studies have shown that short-
acting bronchodilator drugs can reduce dyspnoea and
increase self-paced exercise performance,2–4 mainly by
reducing dynamic hyperinflation which is thought to occur
secondary to tidal expiratory flow limitation.5 Increasing the
inspired oxygen concentration during exercise also improves
exercise capacity6,7 probably through the combination of
reductions in dynamic hyperinflation due to a diminished
ventilatory requirement,8 and better systemic oxygen
delivery.9 These different and commonly used treatments
appear to act through different physiological mechanisms.
To date, no study has directly compared their relative
benefit singly or in combination in the same individual.
Laboratory exercise protocols where the workload is fixed
or allowed to rise in intensity have provided insights into the
mechanisms by which treatment improves exercise perfor-
mance in COPD.10–12 However, these tests do not necessarily
correspond to the way patients behave in everyday life and
for this reason so-called ‘field’ tests of exercise perfor-
mance such as the self-paced 6-min walking distance
(6MWD) have been developed.13,14 Although relatively
simple to perform, standardised results require attention
to detail, particularly in terms of prior familiarisation15 and
encouragement.16 When this is done it has been shown that
self-paced walking produces a progressive increment in
oxygen consumption which approaches the peak oxygen
consumption measured during conventional laboratory ex-
ercise.17 Walking tests have proven sensitive to a range of
interventions noted above as well as pulmonary rehabilita-
tion.18 They are also prognostically useful which has led to
their incorporation in multistage clinical scoring systems.19
This study was designed to evaluate the short-term
impact of oxygen alone or in combination with bronchodi-
lators on exercise capacity and breathlessness in patients
with relatively advanced but clinically stable COPD who
themselves would be suitable for the prescription of
ambulatory oxygen. We hypothesised that the effect of
both interventions would be greater than the placebo and
that each intervention would itself be additive in its effect.
To test this we conducted a randomised single blind placebo
controlled cross-over trial comparing either high-dose
nebulised ipratropium bromide together with salbutamol
or a saline placebo given before first walking test of the
study day and oxygen or air randomly administered during a
subsequent walking test.
Methods
Subjects
Patients aged 40–80 years with clinically stable COPD were
studied as outpatients at the pulmonary division of the
University of Sao Paulo Medical School Hospital. COPD was
defined using the ATS/ERS criteria20 and all patients had
breathlessness on exertion, a history of smoking of at least1 s (FEV1) of less than 60% predicted with an FEV1/ forced
vital capacity (FVC) ratio of o70% and exhibited resting
and/or exercise induced arterial oxygen desaturation with
an oxygen saturation (SaO2) of o90%. Patients were
excluded if they gave a history of an exacerbation of COPD
in the preceding month, had significant cardiovascular
disease, musculoskeletal problems, peripheral vascular
disease or other disabling conditions which would interfere
with their ability to exercise. All patients were taking
short-acting bronchodilators as symptom reliever and the
following medication as maintenance therapy: inhaled
corticosteroids (58%), long-acting b2 agonists (42%) and
theophylline preparations (38%). None were receiving long-
acting inhaled anticholinergics. The study protocol was
approved by the local Research Ethics committee and
informed consent was obtained in all cases.
Pulmonary function testing
Pulmonary function was tested in accordance with recom-
mended methodologies21 and included spirometry, static
lung volumes determined in a constant volume plethysmo-
graph, single breath diffusing capacity for carbon monoxide
(DLco) (Collins/GS, Warren E Collins Inc., USA) and arterial
blood gas tensions breathing air at rest. On the study days,
spirometry was recorded before exercise using a hand held
spirometer (Micro Spirometer, Micro Medical Ltd., Kent, UK)
to confirm clinical stability.
Exercise testing
The 6MWD was measured as previously described with
standardised encouragement during each walk.22 Contin-
uous arterial oxygen saturation (SpO2) and heart rate was
measured with a finger oximeter (Palco Labs model 120
pulse oximeter, Palco Labs Inc, Santa Cruz, CA, USA).
Dyspnoea was assessed using a modified Borg scale in
response to the question ‘How breathless do you feel?’ and
leg fatigue by the question ‘How tired do your legs feel?’.
Patients were familiarised with these questions before
testing. They were asked to point to the Borg score
corresponding to their current sense of intensity at rest,
during exercise and during recovery. All tests were
performed by the same investigator who used the same
form of encouragement in the same way, irrespective of the
treatment given.
Study design
The study protocol is presented in Fig. 1. Patients attended
on three occasions at a same time of day and at least 6 or
24 h after taking short-acting bronchodilators or long-acting
bronchodilators as appropriate. At the first visit, pulmonary
function tests were obtained as described above, arterial
blood was drawn while breathing air at rest and two practice
6-min walks were performed with a 60min rest period
between each test. At visits two and three, in a single blind
cross-over fashion (to bronchodilators and the respective gas
mixtures), baseline spirometry was recorded before and
30min after inhalation of nebulised saline. Next, a walking
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Figure 1 Schematic presentation of study design to show the sequence of aerosol administration, timing of spirometry and 6-min
walking test (6MWD).
A. Cukier et al.748test was performed with the patient breathing compressed
air or supplemental oxygen by nasal prongs at 3 l/min
according to randomisation. Subsequently, the patients
rested for 1 h, repeated their spirometry and then received
salbutamol 5mg together with ipratropium bromide 0.5mg
via an identical nebuliser. After this, spirometry was
repeated as was the 6MWD breathing either compressed or
supplemental oxygen according to the randomisation sche-
dule.Statistical analysis
Results are expressed as mean and standard deviation when
describing populations and as standard error of the mean for
group comparisons. The order of the visits was randomised
in each patient, so the patients received either compressed
air or supplemental oxygen for each walking test at the first
visit with cross-over at the second visit. The study was
powered on the assumption that the combination of oxygen
and the bronchodilators would produce a difference of 54m
in the walking distance. A study of 12 patients would have a
90% power to detect such a difference. To permit compar-
ison with other endpoints e.g. placebo and each active
therapy, the sample size recruited was doubled with
allowance for possible study drop out. Comparison between
treatments were made using analysis of variance of
repeated measures with a P value of o0.05 being accepted
as the lower limit of significance. Pearson correlation was
used to establish association between the performanceduring the acclimatisation walk and the walk breathing air
after placebo.Results
The demographic characteristics of the patients entering
the study are shown in Table 1. They were an elderly group,
predominantly male and had severe airflow obstruction with
significant resting hyperinflation as seen by the increased
residual volume and total lung capacity as a percent of
predicted. Although gas transfer was significantly reduced
they did not have marked resting hypoxaemia, the lowest
PaO2 being 52mmHg. All were significantly limited by
breathlessness as indicated by the low baseline dyspnea
index across the group. They showed minimal bronchodilator
reversibility, only six of the 28 increasing their FEV1 by 12%
of baseline and 200ml after the nebulised bronchodilators.
The 6MWD on the air study day varied between patients
ranging from 72 to 581m while mean end-exercise breath-
lessness was 4.0. The 6MWD and breathlessness scores
breathing air were reproducible, the mean distance after
the acclimatisation walk being 335m compared with the
mean distance breathing air after placebo of 355m
(intraclass correlation coefficient 0.91). Desaturation
breathing air occurred in all cases, the mean change in
oxygen saturation being 9.4%. In six patients the saturation
was p89% at rest (minimum, 85.7%; maximum, 95.5%).
Data summarising the effect of the bronchodilators and
oxygen on spirometry and oxygen saturation, respectively,
are shown in Table 2. Similarly data about the walking
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Bronchodilators and oxygen in COPD 749distance and breathlessness in the different conditions are
presented in Fig. 2. After the bronchodilator the 6MWD
breathing air showed a small statistically significant im-
provement of 22 (10)m but only five subjects (18%)
improved by 54m or more, the minimum clinically important
difference suggested for this test.23 Breathing supplemen-
tary oxygen without extra bronchodilators increased the
minimum SpO2 during exercise relative to the placebo-airTable 1 Baseline anthropometric and resting lung
function data.
No. of patients 28
Sex (M:F) 20:8
Age (years) 66.8 (9.0)
BMI (kg/m2) 23.7 (4.5)
FEV1 (l) 0.81 (0.25)
FEV1 (% predicted) 34.61 (10.35)
FVC (l) 2.11 (0.64)
FVC (% predicted) 65.54 (16.72)
FEV1/FVC (%) 0.39 (0.07)
IC (l) 1.58 (0.46)
IC (% predicted) 72.04 (16.99)
SVC (l) 2.28 (0.66)
TLC (l) 7.09 (1.89)
TLC (% predicted) 134.39 (25.87)
RV (l) 4.79 (1.64)
RV (% predicted) 240.04 (78.68)
DLco (% predicted) 43.04 (23.16)
pH 7.40 (0.02)
PaO2 (mmHg) 61.49 (5.94)
SaO2 (%) 90.9 (2.3)
PaCO2 (mmHg) 40.71 (4.56)
Resting Borg breathlessness score 1.23 (1.12)
Resting Borg leg score 0.21 (0.62)
Baseline dyspnoea index 4.2 (2.2)
Values given are mean (SD).
BMI, body mass index; FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity; IC, inspiratory capacity; SVC, slow
vital capacity; TLC, total lung capacity; RV, residual volume;
DLco, diffusing capacity; PaO2, arterial oxygen tension; SaO2,
arterial oxygen saturation; PaCO2, arterial carbon dioxide
tension.
Table 2 Effect of inhaled salbutamol+ipratropium and placeb
saturation in 28 patients.
FEV1 F
Before
inhalation
After
inhalation
B
i
Placebo inhalation/air walk 0.76 (0.05) 0.80 (0.05) 1
Placebo inhalation/O2 walk 0.72 (0.05) 0.76(0.06) 1
BD inhalation/air walk 0.78 (0.06) 0.91 (0.06) * 1
BD inhalation/O2 walk 0.78 (0.05) 0.90 (0.06) * 1
Data are expressed as mean (SE).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; Sp
with pre inhalation values. **P ¼ 0.01 compared with pre-inhalation v
0.001 compared with placebo inhalation/air walk and BD inhalation/walk in all cases and in 22 patients minimum SpO2 was
489%. With this comparison we saw an increase of 51 (14)m
in 6MWD which was significant (P ¼ 0.001). This improve-
ment was also significantly greater than the walking
distance breathing air after the bronchodilator alone,
altogether 13 patients (46%) increasing their walking
distance by more than 54m. The combination of oxygen
and the bronchodilators increased SpO2489% in 19 patients
and produced the greatest increase in walking distance
relative to air and this was also significantly greater than
either component alone with 19/28 (68%) improving the
walking distance by 54m or more.
Subjects exercised to a similar intensity of breathlessness
after both bronchodilator and oxygen treatment, although
in each case the distance covered was greater. When using
the combination of the bronchodilators and oxygen the
subjects still did not report such severe breathlessness when
they stopped as was the case in the other treatment
conditions. The rate of increase of breathlessness per metre
walked differed with the treatments (Fig. 3). There was no
statistically significant difference in the rate of change of
breathlessness after the bronchodilator; however, breath-
lessness appeared to increase more slowly during the oxygen
alone walk with a value, which approached but this trend
did not reach statistical significance (P ¼ 0.06). There was a
significant change in the rate of increase of breathlessness
when oxygen and bronchodilator treatment were combined
(P ¼ 0.03). The increase in Borg score for leg fatigue at end-
exercise was less pronounced than breathlessness score and
there was no statistically significant difference between the
treatments (mean (SE): placebo/air 0.89 (0.29); bronchodi-
lators/air 1.05 (0.29); placebo/oxygen 0.89 (0.26); bronch-
odilators/oxygen 1.14 (0.31). There was no statistically
significant difference in end-exercise heart rate (mean (SE):
placebo/air 112.0 (2.4) bpm; bronchodilators/air 116.4
(2.3) bpm; placebo/oxygen 113.4 (2.0) bpm; bronchodila-
tors/oxygen 115.1 (2.3) bpm). There was no difference in
the time taken to return to the initial breathlessness score
after the end of exercise between any of the four treatment
conditions (mean (SE): placebo/air 2.88 (0.16)min; bronch-
odilators/air 2.94 (0.19)min; placebo/oxygen 3.10
(0.19)min; bronchodilators/oxygen 2.83 (0.16)min).
The degree of oxygen desaturation during exercise
breathing air and placebo varied from 73% to 89% and waso on spirometric indices, and of oxygen and air on oxygen
VC SpO2
efore
nhalation
After
inhalation
Resting End-exercise
.72 (0.12) 1.89 (0.11)** 91.3 (0.5) 81.9 (1.0)
.56 (0.11) 1.77 (0.14)*** 91.0 (0.4) 92.3 (0.9)****
.84 (0.13) 2.11 (0.13)* 90.8 (0.5) 82.0 (1.0)
.87 (0.12) 2.10 (0.13)* 91.0 (0.4) 90.4 (1.4)****
O2, oxygen saturation; BD, bronchodilators. *Pp0.001 compared
alues. ***P ¼ 0.007 compared with pre-inhalation values. ****Po
air walk.
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Figure 2 The effect of ipratropium plus salbutamol (BD) and oxygen on 6-min walking distance (6MWD) and dyspnoea scores at end
exercise. Values given are mean (SEM). Plac+air: placebo nebulisation and walk on compressed air; BD+air: bronchodilators
nebulisation and walk on compressed air; Plac+O2: placebo nebulisation and walk on oxygen; BD+O2: bronchodilators nebulisation
and walk on oxygen. *Significant difference with Plac+air (P ¼ 0.047); **Significant difference with Plac+air (P ¼ 0.001) and BD+air
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Figure 3 The effect of ipratropium plus salbutamol (BD) and
oxygen on dyspnoea scores/6min walking distance (6MWD) ratio
at end exercise. Values given are mean (SEM). Plac+air: placebo
nebulisation and walk on compressed air; BD+air: bronchodila-
tors nebulisation and walk on compressed air; Plac+O2: placebo
nebulisation and walk on oxygen; BD+O2: bronchodilators
nebulisation and walk on oxygen. *Significant difference with
Plac+air (P ¼ 0.008), BD+air (P ¼ 0.010) and Plac+O2
(P ¼ 0.003).
A. Cukier et al.750not related to the distance walked. The minimum saturation
during exercise was lower with the bronchodilator drug
compared to placebo, irrespective of whether the patient
was breathing oxygen or air but this difference was not
statistically significant. Oxygen breathing failed to prevent
desaturation below 90% in six subjects who received he
saline nebulisation and in nine who received bronchodilator.
However, these patients did not differ significantly in their
response to treatment to those where desaturation was les
severe.
No pre-exercise variable, whether clinical or physiologi-
cal, identified a different pattern of response to any
treatment and specifically, the initial FEV1, inspiratorycapacity, residual volume and total lung capacity and the
magnitude of increase in FEV1 after the bronchodilators
were all unhelpful. Neither was the degree of oxygen
desaturation at rest or during exercise a predictor of either
the initial walking distance breathing air or of the change in
walking distance in the regimes where oxygen was adminis-
tered. However the initial walking distance breathing air
without bronchodilators was inversely related to the
subsequent improve in distance walked (Fig. 4). This
relationship was relatively weak for the bronchodilators
alone but was stronger for walk tests where oxygen was
administered where an effect on exercise performance was
evident even in patients with higher initial walking
distances, something not seen in the bronchodilator-air
walks.Discussion
It is now accepted that exercise tolerance in patients with
significant COPD can be improved by treatment even when
spirometry is unaffected.2,24 A range of short- and long-
acting bronchodilator drugs increase the duration of
endurance exercise mainly by reducing end-expiratory lung
volume at any given time during exercise.10,11,24,25 The
same appears to be true for patients treated with oxygen,
although the rate of increase of end-expiratory lung volume
for any externally imposed load is less, reflecting a
reduction in ventilatory demand, which is thought to be
mediated by chemoreceptor suppression.9 These effects of
treatment, which have been demonstrated using cycle
ergometry and with self-paced walking tests, appear to
occur independently of the degree of oxygen desaturation.26
However the relative magnitude of these effects has not
previously been assessed in the same patients under
conditions in which the treatment would be administered.
The present trial was not designed to assess the mechanisms
by which these treatments might interact but has focussed
on whether worthwhile improvements in exercise capacity
are possible in the type of patients in whom these
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Bronchodilators and oxygen in COPD 751treatments would be used. Our data suggest that treatment
with different modalities of therapy is not mutually
exclusive, even in poorly reversible COPD and worthwhile
improvements in the walking distance and reductions in the
intensity of breathlessness at end-exercise are possible.
Our patients had severe to very severe COPD as currently
defined20 and their daily activities were significantly
impaired as judged by a mean BDI score of four. Most would
be considered to be ‘irreversible’ on acute bronchodilator
testing, although the value of this has been questioned in
both severe and milder COPD.27,28 Despite this all the
treatments tested produced a statistically significant im-
provement in exercise performance when the air breathingwalking test was compared to that after the bronchodilator
with five individuals showing a change that by itself would
be recognised as clinically important.23 Oxygen was more
effective in these short-term tests than high-dose nebulised
bronchodilators with a larger number of subjects exceeding
the minimum clinically important distance in walking
distance as compared with bronchodilator treatment alone.
However, like the bronchodilator therapy the intensity of
breathlessness reported at the end of exercise was similar to
that breathing air. When the treatments were combined
walking distance showed a further significant improvement
that was now accompanied by a reduction in the intensity of
breathlessness at the end of exercise. On this occasion two
thirds of the patients exceeded the minimal clinically
important difference in walking distance. Treatment effec-
tiveness could not be predicted from resting measurements
but patients who walked less initially showed the greatest
benefit. Some patients walked less far after bronchodila-
tors, a change which may have a physiological basis.25 In
contrast oxygen alone or in combination improved walking
distance consistently with the greatest absolute increase
again being found in the most limited patients. This may
reflect a relative ceiling effect of the 6MWD test and
requires further testing using other endurance exercise
protocols.
If anything, this is likely to be an under-estimate of the
true improvement possible in these patients since the most
effective treatment in terms of increased exercise perfor-
mance was associated with less breathlessness and pre-
sumably, a greater capacity to increase exercise further. A
composite endpoint of breathlessness per metre walked has
been reported in pharmacological trials29,30 and this end-
point also distinguished between patients receiving the
different treatments. However, it was no better than
reporting only walking distance in our patients.
The use of a field test like 6MWD restricted the
physiological data that could be collected. Nonetheless,
the rate of increase of breathlessness per metre walked was
unaffected by the bronchodilator but approached a sig-
nificant reduction when oxygen and air breathing were
compared (P ¼ 0.06), in keeping with the known physiolo-
gical effect of supplementary oxygen. The significant
reduction in the rate of increase of breathlessness per
metre walked seen with the combination of bronchodilator
and oxygen supports the idea that each therapy is operating
through an independent mechanism to improve exercise
performance. The maximum heart rate achieved was similar
at the end of each walking test irrespective of therapy
suggesting that treatment was acting by improving ventila-
tory limitation and that patients were achieving a similar
cardiovascular stress on each occasion. These changes were
seen irrespective of the degree of resting or exercise oxygen
desaturation while breathing air or oxygen, in keeping with
previous data.26 We failed to prevent desaturation during
exercise in a number of cases but could see no consistent
differences in treatment response between these patients
and those where desaturation was prevented. Higher
concentrations of inspired oxygen can improve exercise
duration in the laboratory setting7,8 but delivering such high
flows is not possible with the nasal prongs usually used in
ambulatory therapy, which was the comparator system we
used in this study.
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A. Cukier et al.752The randomised order of testing was selected because of
practical constraints on the number of tests we could
perform in these relatively unwell patients. We saw no
evidence of any order affected in our data although the fact
that the post-bronchodilator or post-nebulised saline test
was always second might have limited the improvements
seen due to patient fatigue. However, the greatest
improvement was seen after both bronchodilator and
oxygen, which was the second test to be conducted in
randomised order so we do not think that this is likely to be a
significant limitation of our results. We noted that in some
individuals, the greatest distance walked occurred on the
placebo nebulisation and air test which may reflect the
modest between day variability we established when
comparing the post-practice and placebo air walks. Thus,
some caution is needed in interpreting the results of a single
or coupled walking test with regard to the individual
patient. Our study was powered statistically to show a
difference between the post-bronchodilator and oxygen
combination and the other treatments, which it did.
However, we were not fully powered to establish a
difference between the oxygen alone and the bronchodi-
lator alone treatment. Although such a difference is not
likely to be large, other studies specifically designed to
address this would be needed before any definitive conclu-
sion could be established. The dose of bronchodilator chosen
was high on the known dose response relationship31 the
change in walking distance after the bronchodilator breath-
ing air being comparable to that seen previously after large
doses of salbutamol,32 and is similar to that reported when
significant changes in resting inspiratory capacity were
observed with the same drug combination.33
Our data have practical implications. We have shown that
clinically relevant improvement in exercise performance is
possible when therapies with a different mechanism of
action are combined in the way in which they would be used
in clinical practice. This is analogous to other studies were a
positive interaction between drug therapy and rehabilita-
tion34 has been demonstrated. Moreover, these benefits
were most evident in patients who had the worst walking
distance when breathing room air. Treating patients like
these with oxygen and bronchodilators should produce
noticeable improvements in exerise capacity in most cases
and may improve compliance with ambulatory oxygen
therapy, although this requires formal testing.
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